Prognostic factors add criteria to treat Waldenstrom's macroglobulinemia.

被引：0
作者：
Morel, P
Duhamel, A
Dimopoulos, M
San Miguel, J
Barlogie, B
Kyle, R
Leblond, V
Dhodapkar, M
Mc Coy, J
Treon, S
Gobbi, PG
Merlini, G
机构：
[1] Hop Schaffner, Lens, France
[2] Univ Hosp, Ctr Etud & Rech Informat Med, Lille, France
[3] Univ Athens, Athens, Greece
[4] Hosp Univ, Salamanca, Spain
[5] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[6] Mayo Clin, Rochester, MN USA
[7] Hop La Pitie Salpetriere, Paris, France
[8] SW Oncol Grp, Seattle, WA USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] IRCCS Policlin San Matteo, Biotechnol Res Labs, Pavia, Italy
[11] Univ Pavia, I-27100 Pavia, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [41] Role of B-lymphocyte stimulator (BLyS) in Waldenstrom's macroglobulinemia.
    Elsawa, SF
    Novak, AJ
    Grote, DM
    Zeismer, SC
    Witzig, TE
    Kyle, RA
    Ansell, SM
    BLOOD, 2005, 106 (11) : 178A - 179A
  • [42] Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia.
    Patterson, C. J.
    Soumerai, J.
    Hunter, Z.
    Leleu, X.
    Ghobrial, I.
    Treon, S. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 435S - 435S
  • [43] High levels of soluble immunoregulatory receptors in patients with Waldenstrom's macroglobulinemia.
    Hunter, ZR
    Branagan, AR
    Santos, DD
    Tournilhac, O
    Hatjiharissi, E
    Xu, L
    Manning, RJ
    Treon, SP
    BLOOD, 2004, 104 (11) : 303B - 303B
  • [44] Nervous system lymphoid infiltration in Waldenstrom's macroglobulinemia. A case report
    Massengo, S
    Riffaud, L
    Morandi, X
    Bernard, M
    Verin, M
    JOURNAL OF NEURO-ONCOLOGY, 2003, 62 (03) : 353 - 358
  • [45] Serous detachment of sensory retina in Waldenstrom's macroglobulinemia. A case report
    Feigl, B
    Sill, H
    Haas, A
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1999, 215 (01) : 64 - 67
  • [46] Peripheral neuropathy associated with monoclonal cryoglobulin related to Waldenstrom's macroglobulinemia.
    Vital, A
    Favereaux, A
    Taupin, JL
    Canron, MH
    Vital, C
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05) : 542 - 542
  • [47] Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression
    Dimopoulos, MA
    Alexanian, R
    Gika, D
    Anagnostopoulos, A
    Zervas, C
    Zomas, A
    Kyrtsonis, MC
    Anagnostopoulos, N
    Pangalis, GA
    Weber, DM
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2057 - 2061
  • [48] Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
    Kyle, RA
    Treon, SP
    Alexanian, R
    Barlogie, B
    Björkholm, M
    Dhodapkar, M
    Lister, TA
    Merlini, G
    Morel, P
    Stone, M
    Branagan, AR
    Leblond, W
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 116 - 120
  • [49] IgM MGUS and asymptomatic Waldenstrom's macroglobulinemia: Prognostic factors and evolution
    Morra, E.
    Cesana, C.
    Barbarano, L.
    Varettoni, M.
    Bemuzzi, P.
    Tedeschi, A.
    Cavanna, I.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 82 - 83
  • [50] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Hamilos, G
    Zervas, K
    Symeonidis, A
    Kouvatseas, G
    Roussou, P
    Gika, D
    Karmiris, T
    Bourantas, K
    Zomas, A
    Mitsouli, C
    Xilouri, I
    Vervessou, E
    Matsis, K
    Anagnostopoulos, N
    Economopoulos, T
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1299 - 1305
12345